Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)

Inclusion Criteria: * diagnosis of persistent asthma of ≥6 months duration * body weight ≥18 kg * able to discontinue prescribed inhaled corticosteroid (ICS) or ICS combined with long-acting beta-agonist (LABA) before starting study medication * use of a low or medium daily dose of ICS (either alone or in combination with a LABA) with no use of oral corticosteroids within 3 months prior to Screening Visit * stable asthma regimen (daily dose unchanged) for ≥2 weeks prior to Screening Visit * documented positive responsiveness to bronchodilators * ability to use a peak flow meter correctly and to perform spirometry and PEF measurements * ability to use an inhaler correctly * consent/assent for the trial and for pharmacogenetic testing (Note: If unwilling to consent/assent for pharmacogenetic testing, inclusion in the study is still allowed, but no pharmacogenetic samples will be obtained.) Exclusion Criteria: * use of a high dose of ICS for ≥30 days within 6 months prior to Screening Visit * treatment in the emergency room (for a severe asthma exacerbation requiring systemic corticosteroid treatment) or hospitalization for management of airway obstruction within 3 months prior to Screening Visit * ever required ventilator support for respiratory failure secondary to asthma * upper or lower respiratory tract infection (viral or bacterial) within 2 weeks prior to Screening Visit * clinically significant abnormal vital sign * evidence of oropharyngeal candidiasis * history of c…